POSTER PRESENTATION

Open Access

Electrochemotherapy and inducible T cell co-stimulator (iCOS) antibody therapy: a novel combinational therapy for the enhanced treatment in cancers of poor prognosis

Morgan O'Brien^{1*}, Patrick Forde¹, Derek Power², Declan Soden¹

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

The correlation between the level of immune involvement and immune cell infiltration within a treated tumour and the clinical outcome for patients has been well established in many solid tumour types. High numbers of tumour infiltrating lymphocytes has been associated with a significantly improved prognosis. Some of the key cell types involved are $CD3^+$ and $CD8^+$ T cells, B cells and APCs such as dendritic cells (DCs).

Cork Cancer Research Centre (CCRC) has long utilised an ablative cancer treatment that involves delivering a pulse of electrical energy (electroporation) directly to the tumour. This treatment results in the formation of reversible pores in the cell membrane, allowing up to a 1000 fold increase in chemotherapy drug absorption (Electrochemotherapy). A significant benefit of this non thermal ablation is the release of tumour associated antigens into the microenvironment, leading to activation of APCs and subsequent cross presentation of the antigens to circulating T and B cells. While ECT facilitates the priming of a favourable immune response, the combination of iCOS antibody, capable of stimulating T cell proliferation, causes a very robust mediated regression of treated tumours. In addition, ICOS is involved in humoral immune responses (B cell germinal center formation) and increases the production of IL-4.

Preclinical work in aggressive murine models has yielded very encouraging results. The combinational therapy has achieved cures in both colorectal (CT26) and metastatic lung (LLC) cancer cell lines. Follow up immunohistochemical staining confirmed the presence of tumour

infiltrating $CD3^+$ and $CD8^+$ T cells, $CD45R^+$ B cells and $CD11c^+$ DCs, post treatment.

Authors' details

¹Cork Cancer Research Centre, Cork City, Ireland. ²Cork University Hospital, Cork City, Ireland.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P116

Cite this article as: O'Brien et al.: Electrochemotherapy and inducible T cell co-stimulator (iCOS) antibody therapy: a novel combinational therapy for the enhanced treatment in cancers of poor prognosis. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P116.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

¹Cork Cancer Research Centre, Cork City, Ireland
Full list of author information is available at the end of the article

© 2014 Brien et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.